 Home > Active Ingredient News > Antitumor Therapy > Lancet oncol: Pembrolizumab can significantly improve the quality of life of patients with metastatic colorectal cancer with MSI-H or dMMR

Lancet oncol: Pembrolizumab can significantly improve the quality of life of patients with metastatic colorectal cancer with MSI-H or dMMR

 Last Update: 2021-04-13
 Source: Internet
 Author: User

Tags

calvert home health

foods health claims

Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

Colorectal cancer is the third most common cancer and the second leading cause of cancer death in the world .

Of colorectal cancer is the third most common cancer and the second cause of cancer death in colorectal cancer

The KEYNOTE-177 trial is an open-label, randomized phase 3 trial conducted at 192 cancer centers in 23 countries.

The results of the primary endpoint analysis showed that compared with chemotherapy, pembrolizumab monotherapy, as the first-line treatment for metastatic colorectal cancer with high microsatellite instability or defective mismatch repair, can significantly prolong the progression-free survival of patients .

Compared with chemotherapy, pembrolizumab monotherapy, as the first-line treatment for metastatic colorectal cancer with high microsatellite instability or defective mismatch repair, can significantly prolong the progression-free survival of patients

In order to further support the efficacy and safety results of the trial, this article reports the analysis results of the HRQOL of the patients in the trial .

This article reports the results of the analysis of the HRQOL of the trial patients

From February 11, 2016 to February 19, 2018, a total of 307 patients were randomly assigned to pembrolizumab group (n=153) or chemotherapy group (n=154), of which 294 (pembrolizumab) 152 people in the anti-resistant group and 142 people in the chemotherapy group) were included in the HRQOL analysis.

EORTC QLQ-C30 score changes

As of February 19, 2020, the median follow-up time after randomization was 32.

The least squares mean square (LSM) analysis from baseline to the scheduled 18th week showed that compared with the chemotherapy group, the EORTC QLQ-C30 GHS/QOL score of the pembrolizumab group was significantly improved

Average change in EORTC QLQ-C30 score from baseline to week 18

In summary, for previously untreated metastatic colorectal cancer with high microsatellite instability or mismatch repair defects, pembrolizumab monotherapy can significantly increase the HRQOL of patients compared with chemotherapy .

For previously untreated metastatic colorectal cancer with high microsatellite instability or defective mismatch repair, pembrolizumab monotherapy can significantly improve the patient's HRQO compared to chemotherapy

Original source:

Thierry Andre, et al.

org/10.
1016/S1470-2045(21)00064-4" target="_blank" rel="noopener">Health-related quality of life in patients with microsatellite instability-high or mismatch repair deficient metastatic colorectal cancer treated with first-line pembrolizumab versus chemotherapy (KEYNOTE-177): an open-label, randomised, phase 3 trial in this message

This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.